<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Management in hospitalized adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Management in hospitalized adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Management in hospitalized adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arthur Y Kim, MD, FIDSA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H801110452"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coronaviruses are important human and animal pathogens. At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. It rapidly spread, resulting in a global pandemic. The disease is designated COVID-19, which stands for coronavirus disease 2019 [<a href="#rid1">1</a>]. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</p><p>This topic will discuss the management of COVID-19 in hospitalized adults. Our approach to hospital management evolves rapidly as clinical data emerge. Clinicians should consult their own local protocols for management, which may differ from our approach. Guidance has been issued by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Ftechnical-guidance&amp;token=6mXYIWRNeGuRBDztc0ikcx%2FscIH17x5CKTjm%2FQ5raI%2BhwCh5c71WqQ9R9tsNhJx%2BEpnuKumThFrcmSBNouVEawrja%2FasPUViVSynQSbKTCw%3D&amp;TOPIC_ID=127429" target="_blank">World Health Organization</a> and, in the United States, by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.covid19treatmentguidelines.nih.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlKLiC18SWIohr6cqnWWE%2FbiQ0KVDPUI7oQndFKYd4lKMK9do5Jm5jXA7bHDRP990JQ%3D%3D&amp;TOPIC_ID=127429" target="_blank">National Institutes of Health</a> COVID-19 Treatment Guidelines Panel [<a href="#rid2">2</a>]. Links to these and other related society guidelines are found elsewhere. (See <a class="local">'Society guideline links'</a> below.)</p><p>The management of patients with COVID-19 in the home and outpatient setting is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-128064">(Related Pathway(s):  <a class="utd-content-128064" href="/pathway/128064?topicRef=127429&amp;source=see_link">COVID-19: Anticoagulation in adults with COVID-19</a>.)</span></p><p>Respiratory and critical care of patients with COVID-19 are also discussed separately. (See  <a class="medical medical_review" href="/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)"</a> and  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p>The epidemiology, clinical features, diagnosis, and prevention of COVID-19 are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a> and  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H478803960"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Our objective in the evaluation of hospitalized patients with documented or suspected COVID-19 is to evaluate for features associated with severe illness  (<a class="graphic graphic_table graphicRef127820" href="/d/graphic/127820.html" rel="external">table 1</a>) and identify organ dysfunction or other comorbidities that could complicate potential therapy. The diagnosis of COVID-19 is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>.)</p><p>This approach to evaluation reflects our institution’s practice, which was established with interdisciplinary input. Although we check several laboratory tests to evaluate patients with documented or suspected COVID-19, the prognostic value of many of them remains uncertain, and other institutions may not include all these tests. </p><p>At least initially, we check the following laboratory studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with differential, with a focus on the total lymphocyte count trend, daily </p><p class="bulletIndent1"><span class="glyph">●</span>Basic metabolic panel daily</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic panel every other day (or daily if elevated or in the intensive care unit)</p><p></p><p>We check the following studies for patients with severe COVID-19 (with hypoxia or in need of oxygen/ventilatory support) and repeat them if abnormal or with clinical worsening:</p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (CRP)</p><p class="bulletIndent1"><span class="glyph">●</span>Lactate dehydrogenase</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)/partial thromboplastin time (PTT)/fibrinogen/D-dimer</p><p class="bulletIndent1"><span class="glyph">●</span>Troponin</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG), with at least one repeat test after starting any QTc-prolonging agent (see  <a class="medical medical_review" href="/d/html/127551.html" rel="external">"COVID-19: Arrhythmias and conduction system disease", section on 'Monitoring for QT prolongation'</a>)</p><p></p><p>We also check hepatitis B virus serologies, hepatitis C virus antibody, and HIV antigen/antibody testing if these have not been previously performed. Chronic viral hepatitis could affect interpretation of transaminase elevations and exacerbate hepatotoxicity of certain therapies; underlying HIV infection may change the assessment of the patient's risk for deterioration and would warrant initiation of antiretroviral therapy. </p><p>We check a portable chest radiograph in hospitalized patients with COVID-19; for most patients, this is sufficient for initial evaluation of pulmonary complications and extent of lung involvement. We reserve chest CT for circumstances that might change clinical management, in part to minimize infection control issues related to transport. This is consistent with recommendations from the American College of Radiology [<a href="#rid3">3</a>]. Although certain characteristic chest CT findings may be seen in COVID-19, they cannot reliably distinguish COVID-19 from other causes of viral pneumonia. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Imaging findings'</a>.)</p><p>We do not routinely obtain echocardiograms on patients with COVID-19; developments that might warrant an echocardiogram include increasing troponin levels with hemodynamic compromise or other cardiovascular findings suggestive of cardiomyopathy. Acute myocardial injury has been a described complication of COVID-19. (See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Targeted cardiac evaluation'</a>.) </p><p>Secondary bacterial infection occurs in the minority of patients with COVID-19; if this is suspected (eg, based on chest imaging or sudden deterioration), we check two sets of blood cultures and sputum Gram stain and culture. Procalcitonin can be checked to assess the risk of secondary bacterial infection; however, since elevated procalcitonin levels have been reported as COVID-19 progresses, they may be less specific for bacterial infection later in the disease course [<a href="#rid4">4-7</a>]. </p><p>As above, the prognostic value of the results of some of the tests we use to evaluate patients with COVID-19 is uncertain, and the optimal use of these markers remains unknown. As an example, although some clinicians also note the potential utility of troponin levels to inform the risk of severe COVID-19 and provide a baseline for comparison in patients who develop manifestations of myocardial injury [<a href="#rid8">8</a>], others reserve troponin level testing for patients who have specific clinical suspicion for acute coronary syndrome [<a href="#rid9">9</a>]. One concern is that the results could lead to unnecessary use of medical resources (eg, serial troponins, electrocardiograms and cardiology consults for elevated troponin). If troponin is checked in a patient with COVID-19, clinicians should be aware that an elevated level does not necessarily indicate acute coronary syndrome. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Troponin'</a>.) </p><p class="headingAnchor" id="H3923883497"><span class="h1">GENERAL MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H1148632933"><span class="h2">Empiric treatment for influenza during influenza season</span><span class="headingEndMark"> — </span>The clinical features of seasonal influenza and COVID-19 overlap, and they can only be reliably distinguished by microbiologic testing. Additionally, coinfection with both is possible, so the diagnosis of COVID-19 does not rule out the possibility of influenza. We agree with the United States National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel, which recommends empiric therapy for influenza for patients hospitalized with suspected or documented COVID-19 in locations where influenza virus is circulating [<a href="#rid2">2</a>]. Antiviral therapy for influenza should be discontinued if molecular testing for influenza is negative from upper respiratory tract specimens in non-intubated patients and from both upper and lower respiratory tract specimens in intubated patients. Antiviral therapy for seasonal influenza is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="headingAnchor" id="H641463052"><span class="h2">Empiric treatment for bacterial pneumonia in selected patients</span><span class="headingEndMark"> — </span>For patients with documented COVID-19, we do not routinely administer empiric therapy for bacterial pneumonia. Bacterial superinfection has been reported in the minority (fewer than 20 percent) of patients hospitalized for COVID-19. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Acute course and complications'</a>.)</p><p>However, since the clinical features of COVID-19 may be difficult to distinguish from bacterial pneumonia, empiric treatment for community-acquired pneumonia is reasonable when the diagnosis is uncertain. Empiric treatment for bacterial pneumonia may also be reasonable in patients with documented COVID-19 if there is clinical suspicion for it (eg, new fever after defervescence with new consolidation on chest imaging). If empiric antibiotic therapy is initiated, we attempt to make a microbial diagnosis (eg, through sputum Gram stain and culture, urinary antigen testing) and reevaluate the need to continue antibiotic therapy daily. In such settings, a low procalcitonin may be helpful to suggest against a bacterial pneumonia; however, elevated procalcitonin has been described in COVID-19, particularly late in the course of illness, and does not necessarily indicate bacterial infection [<a href="#rid4">4-7</a>]. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Guiding antibiotic therapy'</a>.)</p><p>The diagnosis of and empiric antibiotic regimens for community-acquired and health care-associated pneumonia are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H947281859"><span class="h2">Prevention of and evaluation for venous thromboembolism</span><span class="headingEndMark"> — </span>We favor pharmacologic prophylaxis of venous thromboembolism for all hospitalized patients with COVID-19. Dosing and selection of pharmacologic agents to prevent venous thromboembolism in hospitalized patients with COVID-19, including whether to use therapeutic-dose anticoagulation, are discussed in detail elsewhere  (<a class="graphic graphic_algorithm graphicRef128045" href="/d/graphic/128045.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'Inpatient VTE prophylaxis'</a>.)</p><p>Several studies suggest a high rate of thromboembolic complications among hospitalized patients with COVID-19, particularly those who are critically ill. The thromboembolic risk with COVID-19 as well as the evaluation for and management of these complications are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'VTE'</a> and  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2294322673"><span class="h2">NSAID use</span><span class="headingEndMark"> — </span>As with the general approach to fever reduction in adults, we use <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> as the preferred antipyretic agent in patients with COVID-19 and, if non-steroidal anti-inflammatory drugs (NSAIDs) are needed, use the lowest effective dose to minimize common adverse effects (see  <a class="medical medical_review" href="/d/html/2734.html" rel="external">"Pathophysiology and treatment of fever in adults", section on 'Treatment of fever and hyperpyrexia'</a>). We do not discontinue NSAIDs in patients who are on them chronically for other conditions, unless there are other reasons to stop them (eg, renal injury, gastrointestinal bleeding). </p><p>Initial concerns about potential negative effects of NSAIDs in patients with COVID-19 [<a href="#rid10">10</a>] have not been supported by most observational data, which have failed to identify worse COVID-19 outcomes with NSAID use compared with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or no antipyretic use [<a href="#rid11">11-15</a>]. As an example, in a study of patients who were hospitalized for COVID-19 in the United Kingdom, rates of in-hospital mortality, invasive ventilation, and oxygen requirement were not different among the 4205 patients who had used systemic NSAIDs the two weeks prior to hospitalization compared with propensity score-matched controls [<a href="#rid15">15</a>]. </p><p>The European Medicines Agency (EMA), WHO, and the United States NIH COVID-19 Treatment Guidelines Panel do not recommend that NSAIDs be avoided when clinically indicated [<a href="#rid2">2,16,17</a>]. </p><p class="headingAnchor" id="H2432617353"><span class="h2">Nebulized medications</span><span class="headingEndMark"> — </span>If a nebulizer must be used, appropriate infection control precautions should be taken. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Aerosol-generating procedures/treatments'</a> and  <a class="medical medical_review" href="/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)", section on 'Nebulized medications'</a>.) </p><p class="headingAnchor" id="H563527731"><span class="h2">Managing chronic medications</span></p><p class="headingAnchor" id="H3527358036"><span class="h3">ACE inhibitors/ARBs</span><span class="headingEndMark"> — </span>Patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should continue treatment with these agents if there is no other reason for discontinuation (eg, hypotension, acute kidney injury). This approach is supported by multiple guidelines panels [<a href="#rid18">18-22</a>]. Despite speculation that patients with COVID-19 who are receiving these agents may be at increased risk for adverse outcomes, accumulating evidence does not support an association between renin angiotensin system inhibitor use and more severe disease. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Renin angiotensin system inhibitors'</a>.)</p><p>Conversely, data suggest that modulation of the renin-angiotensin pathway does not improve COVID-19 outcomes and that ACE inhibitors or ARBs should not be initiated for the purpose of treating COVID-19 [<a href="#rid23">23,24</a>]. </p><p class="headingAnchor" id="H2496061477"><span class="h3">Statins and aspirin</span><span class="headingEndMark"> — </span>We make a point of continuing statins in hospitalized patients with COVID-19 who are already taking them. We also continue <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> unless there are concerns about bleeding risk. A high proportion of patients with severe COVID-19 have underlying cardiovascular disease, diabetes mellitus, and other indications for use of statins and aspirin. Moreover, acute cardiac injury is a reported complication of COVID-19. Although clinicians may be concerned about hepatotoxicity from statins, particularly since transaminase elevations are common in COVID-19, most evidence indicates that liver injury from statins is uncommon. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Hepatic dysfunction'</a>.) </p><p>We do not initiate statins or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients with COVID-19 who do not have pre-existing indications for them. Although observational studies had suggested a potential mortality benefit in hospitalized patients with COVID-19, randomized trials have not confirmed these findings [<a href="#rid25">25,26</a>]. </p><p>As an example, in a randomized trial of over 2600 critically ill adults with COVID-19, daily <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> did not improve in-hospital survival compared with no statin therapy (73 versus 70 percent, adjusted odds ratio 1.04, 95% CI 0.85-1.27) [<a href="#rid26">26</a>]. Although there were trends toward more days without organ support, less progression to mechanical ventilation, and shorter intensive care unit (ICU) length of stay with simvastatin, these differences were not statistically significant. The trial results did not confirm those of retrospective studies in which statin use was associated with a lower rate of ICU admission or death [<a href="#rid27">27-31</a>]. Whether the timing of statin administration has an effect is uncertain. </p><p>Similarly, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> use during hospitalization for COVID-19 did not reduce 28-day mortality or the risk of progression to mechanical ventilation compared with standard of care or placebo in randomized trials [<a href="#rid32">32,33</a>]. A follow-up analysis of one of those trials suggested that aspirin could be associated with decreased 180-day mortality, but the reduction was not statistically significant [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'Aspirin/antiplatelet agents'</a>.)</p><p class="headingAnchor" id="H2053567574"><span class="h3">Immunomodulatory agents</span><span class="headingEndMark"> — </span>Use of immunosuppressing agents has been associated with increased risk for severe disease with other respiratory viruses, and the decision to discontinue <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, biologics, or other immunosuppressive<em> </em>drugs in the setting of COVID-19 must be determined on a case-by-case basis. </p><p>These issues are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Adjusting immunosuppression'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'Medication management with documented or presumptive COVID-19'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults", section on 'Adjusting IBD medications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127978.html" rel="external">"COVID-19: Cutaneous manifestations and issues related to dermatologic care", section on 'Continuation of immunosuppressive therapies'</a>.)</p><p></p><p class="headingAnchor" id="H1402561820"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>Infection control is an essential component of management of patients with suspected or documented COVID-19. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.) </p><p class="headingAnchor" id="H3855514466"><span class="h1">COVID-19-SPECIFIC THERAPY</span></p><p class="headingAnchor" id="H1912427935"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The optimal approach to treatment of COVID-19 is evolving. Based on the pathogenesis of COVID-19, approaches that target the virus itself (eg, antivirals, passive immunity, interferons) are more likely to work early in the course of infection, whereas approaches that modulate the immune response may have more impact later in the disease course  (<a class="graphic graphic_figure graphicRef130197" href="/d/graphic/130197.html" rel="external">figure 1</a>). </p><p class="headingAnchor" id="H2165497896"><span class="h3">Defining disease severity</span><span class="headingEndMark"> — </span>Mild disease is characterized by fever, malaise, cough, upper respiratory symptoms, and/or less common features of COVID-19, in the absence of dyspnea. Most of these patients do not need hospitalization. </p><p>If patients develop dyspnea, that raises concern that they have at least moderate severity disease, and these patients often warrant hospitalization. Patients can have infiltrates on chest imaging and still be considered to have moderate disease, but the presence of any of the following features indicates severe disease: </p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia (oxygen saturation ≤94 percent on room air)</p><p class="bulletIndent1"><span class="glyph">●</span>Need for oxygenation or ventilatory support</p><p></p><p>Given oxygen saturation targets in patients with hypoxemia, most individuals with severe disease warrant some form of oxygen supplementation. Assessment of oxygen saturation in individuals with dark skin pigmentation warrants special attention, as pulse oximetry may overestimate the oxygen saturation in such patients. This is discussed in detail elsewhere, as are recommended thresholds for oxygen supplementation. (See  <a class="medical medical_review" href="/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)", section on 'Oxygenation targets'</a>.) </p><p>This definition of severe disease is consistent with the definition used by the US Food and Drug Administration [<a href="#rid35">35</a>]. Some studies have used other features in addition to hypoxemia to characterize severe disease, such as tachypnea, respiratory distress, and &gt;50 percent involvement of the lung parenchyma on chest imaging [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H3767321121"><span class="h3">Patients without oxygen requirement</span><span class="headingEndMark"> — </span>For most hospitalized patients who do not need oxygen supplementation, our approach to management depends on whether they have clinical  (<a class="graphic graphic_table graphicRef127477" href="/d/graphic/127477.html" rel="external">table 2</a>) or laboratory risk factors  (<a class="graphic graphic_table graphicRef127820" href="/d/graphic/127820.html" rel="external">table 1</a>) associated with progression to more severe disease and the reason for hospitalization. </p><p class="bulletIndent1"><span class="glyph">●</span>For those with risk factors for severe disease who were hospitalized for COVID-19, we suggest <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>. Trial data suggest that remdesivir may improve time to recovery in such patients, although the magnitude of effect is uncertain [<a href="#rid37">37-39</a>]. We recommend not using <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, which may be associated with worse outcomes in such patients [<a href="#rid40">40</a>]. Administration and dosing of remdesivir and evidence informing its use are discussed elsewhere. (See <a class="local">'Remdesivir'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with risk factors for severe disease who were hospitalized for a non-COVID-19 reason and have incidental SARS-CoV-2 infection (or acquired infection during hospitalization), we evaluate eligibility for therapies authorized for certain high-risk outpatients  (<a class="graphic graphic_algorithm graphicRef139859" href="/d/graphic/139859.html" rel="external">algorithm 2</a>). Administration, dosing, and efficacy of these therapies for nonsevere COVID-19 are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have no oxygen requirement and who have no risk factors for progression to severe disease, we suggest supportive care only.</p><p></p><p>These patients warrant monitoring for clinical worsening. If they develop an oxygen requirement related to COVID-19, we treat them as described below. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> below.)</p><p>In the United States, an emergency use authorization (EUA) has been granted for convalescent plasma for selected patients. However, we do not use convalescent plasma outside of clinical trials for hospitalized patients. (See <a class="local">'Limited role for antibody-based therapies (monoclonal antibodies and convalescent plasma)'</a> below.)</p><p class="headingAnchor" id="H3286372799"><span class="h3">Patients with oxygen requirement/severe disease</span><span class="headingEndMark"> — </span>We prioritize COVID-19-specific therapy for hospitalized patients who have severe disease and require oxygen supplementation due to COVID-19. The approach depends on the oxygen or ventilatory requirement; doses and duration are listed in the algorithm  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients receiving low-flow supplemental oxygen</strong> – For most patients on low-flow supplemental oxygen, we suggest both low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (6 mg) and <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>. However, for those who are stably on minimal supplemental oxygen (eg, 1 to 2 L/min), it is reasonable to forgo dexamethasone and use remdesivir alone, particularly if there are concerns about use of glucocorticoids or if the patient is immunocompromised and early in the course of illness (eg, &lt;10 days). Trial data suggest that dexamethasone improves mortality in patients who are on noninvasive oxygen supplementation; it is uncertain if there are particular patients in this relatively heterogeneous group who would benefit more than others, and those stable on minimal oxygen may not have the excess inflammation that dexamethasone is intended to address. Some but not all trials also suggest that remdesivir may improve survival and reduce mechanical ventilation in patients on noninvasive oxygen supplementation. (See <a class="local">'Dexamethasone and other glucocorticoids'</a> below and <a class="local">'Remdesivir'</a> below.)</p><p></p><p class="bulletIndent1">For patients who are on low-flow supplemental oxygen but have elevated inflammatory markers, have escalating oxygen requirements despite initiation of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, and are within 96 hours of hospitalization, we suggest adding <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> on a case-by-case basis. We define escalating oxygen requirements as a rapid increase of 6 L/min or more within 24 hours, a 10 L/min or more requirement, or escalating beyond nasal cannula. Trial data suggest that adding either baricitinib or tocilizumab to dexamethasone in such individuals may further reduce mortality; however, for stable patients with low expected mortality, the absolute mortality benefit may be very low and not outweigh the potential risks. (See <a class="local">'Baricitinib and JAK inhibitors'</a> below and <a class="local">'IL-6 pathway inhibitors (eg, tocilizumab)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients receiving high-flow supplemental oxygen or non-invasive ventilation </strong>– For patients on high-flow oxygen or noninvasive ventilation, we recommend low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (6 mg). For those who are within 24 to 48 hours of admission to an ICU or receipt of ICU-level care and within 96 hours of hospitalization, we also suggest adjunctive <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>. Trial data suggest that dexamethasone improves mortality in patients who are on noninvasive oxygen supplementation and that the addition of baricitinib or tocilizumab further reduces mortality. (See <a class="local">'Dexamethasone and other glucocorticoids'</a> below and <a class="local">'Baricitinib and JAK inhibitors'</a> below and <a class="local">'IL-6 pathway inhibitors (eg, tocilizumab)'</a> below.)</p><p></p><p class="bulletIndent1">We also suggest <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>, particularly in immunocompromised patients, based on the theoretic benefit of adding antiviral therapy to anti-inflammatory treatment. (See <a class="local">'Remdesivir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who require mechanical ventilation or extracorporeal membrane oxygenation</strong> <strong>(ECMO)</strong> – For such patients, we recommend low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (6 mg); for those who are within 24 to 48 hours of admission to an ICU and within 96 hours of hospitalization, we also suggest adjunctive <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> or <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>. Trial data suggest that dexamethasone and the addition of tocilizumab or baricitinib each improve mortality in this population when used early in hospitalization. We suggest not routinely starting <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> in this population. Although it is reasonable to add remdesivir in individuals who have only been intubated for a short time (eg, 24 to 48 hours), the clinical benefit of this is uncertain. Those who had initiated remdesivir when they had lower oxygenation support needs should continue the course of remdesivir. (See <a class="local">'Dexamethasone and other glucocorticoids'</a> below and <a class="local">'Baricitinib and JAK inhibitors'</a> below and <a class="local">'IL-6 pathway inhibitors (eg, tocilizumab)'</a> below.)</p><p></p><p>For all these patients, if <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is not available, other glucocorticoids at equivalent doses are reasonable alternatives. (See <a class="local">'Dexamethasone and other glucocorticoids'</a> below.)</p><p>When <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> is warranted, we only use these agents in patients receiving glucocorticoids, and we do not use baricitinib in patients who have received tocilizumab and vice versa. There are no data directly comparing baricitinib with tocilizumab, and the choice between them depends on availability. Certain other immunomodulatory agents (eg, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> or <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) are potential alternatives if neither is available. (See <a class="local">'Baricitinib and JAK inhibitors'</a> below and <a class="local">'IL-6 pathway inhibitors (eg, tocilizumab)'</a> below and <a class="local">'Limited roles for alternative immunomodulators'</a> below.) </p><p><a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">Remdesivir</a> is approved or available for emergency use in some countries but is not universally available [<a href="#rid41">41-43</a>]. (See <a class="local">'Remdesivir'</a> below.)</p><p class="headingAnchor" id="H2014414098"><span class="h2">Specific treatments</span></p><p class="headingAnchor" id="H2223242197"><span class="h3">Dexamethasone and other glucocorticoids</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>dexamethasone</strong> – We recommend <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> for severely ill patients with COVID-19 who are on supplemental oxygen or ventilatory support  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>). We use dexamethasone at a dose of 6 mg daily for 10 days or until discharge, whichever is shorter. If dexamethasone is not available, it is reasonable to use other glucocorticoids at equivalent doses (eg, total daily doses of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 150 mg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 32 mg, or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg), although data supporting use of these alternatives are more limited than those for dexamethasone. In contrast, we recommend that dexamethasone (or other glucocorticoids) not be used for either prevention or treatment of mild to moderate COVID-19 (patients not on oxygen). These recommendations are largely consistent with those of other expert and governmental groups [<a href="#rid2">2,44-47</a>]. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> above.) </p><p></p><p class="bulletIndent1">Glucocorticoids may also have a role in the management of refractory shock in critically ill patients with COVID-19. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for adverse effects</strong> – Patients receiving glucocorticoids should be monitored for adverse effects. In severely ill patients, these include hyperglycemia and an increased risk of infections (including bacterial, fungal, and <em>Strongyloides</em> infections); the rates of these infections in patients with COVID-19 are uncertain. Nevertheless, pre-emptive treatment of <em>Strongyloides</em> prior to glucocorticoid administration is reasonable for patients from endemic areas (ie, tropical and subtropical regions). This is discussed elsewhere (see  <a class="medical medical_review" href="/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Preventive treatment'</a>). Major side effects of glucocorticoids are also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data from randomized trials overall support the role of glucocorticoids for severe COVID-19 [<a href="#rid48">48-51</a>]. In a meta-analysis of seven trials that included 1703 critically ill patients with COVID-19, glucocorticoids reduced 28-day mortality compared with standard care or placebo (32 versus 40 percent, odds ratio [OR] 0.66, 95% CI 0.53-0.82) and were not associated with an increased risk of severe adverse events [<a href="#rid48">48</a>]. Another meta-analysis of randomized trials also reported a decreased risk of mechanical ventilation (OR 0.74, 95% CI 0.58-0.92) compared with standard care [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">The majority of the efficacy data on glucocorticoids in these meta-analyses comes from a large open-label trial in the United Kingdom in which 2104 and 4321 patients with confirmed or suspected COVID-19 were randomly assigned to receive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (given at 6 mg orally or intravenously daily for up to 10 days) or usual care, respectively [<a href="#rid40">40</a>]. Dexamethasone reduced 28-day mortality in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on invasive mechanical ventilation or ECMO at baseline – 36 percent relative reduction (29.3 versus 41.4 percent, RR 0.64, 95% CI 0.51-0.81). Age-adjusted analysis suggested a 12.3 percent absolute mortality reduction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on noninvasive oxygen therapy (including noninvasive ventilation) at baseline – 18 percent relative reduction (23.3 versus 26.2 percent, RR 0.82, 95% CI 0.72-0.94). Age-adjusted analysis suggested a 4.1 percent absolute mortality reduction. </p><p></p><p class="bulletIndent1">In contrast, a benefit was not seen among patients who did not require either oxygen or ventilatory support; there was a nonstatistically significant trend towards higher mortality (17.8 versus 14 percent, RR 1.19, 95% CI 0.91-1.55). Results were similar when analysis was restricted to the patients with laboratory-confirmed COVID-19 (89 percent of the total population). Other studies have also suggested potential harm with glucocorticoids in this population [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1">For individuals who are ready for discharge before completing a 10-day course of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, continuing the medication following discharge has not been associated with additional benefit [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">The optimal dose of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is uncertain. In a randomized trial from Europe and India that included nearly 1000 adults with COVID-19 who needed at least 10 L of supplemental oxygen or ventilatory support, 12 mg daily of dexamethasone resulted in trends toward more days alive without life support at 28 days (22 versus 20.5 days; adjusted mean difference 1.3 days, 95% CI 0-2.6) and lower 28-day mortality (27 versus 32 percent, adjusted RR 0.86, 95% CI 0.68-1.08) compared with 6 mg daily, but these differences were not statistically significant [<a href="#rid54">54</a>]. Other smaller trials have not identified a reduction in mechanical ventilation or mortality rates with high- versus lower-dose dexamethasone [<a href="#rid55">55-57</a>]. Furthermore, in another trial that included 1272 patients who required only low amounts of supplemental oxygen, mortality rates were higher with high-dose dexamethasone (20 mg daily for five days then 10 mg daily for five days) compared with the usual 6 mg daily dose (19 versus 12 percent; RR 1.59, 95% CI 1.2-2.1) [<a href="#rid58">58</a>]. Similarly, data do not suggest a benefit of adding other glucocorticoids to dexamethasone [<a href="#rid59">59</a>]. Unless additional trial data indicate that a higher dose is superior in a particular patient population, we continue to use the same 6 mg dose studied in the large trial from the United Kingdom. </p><p></p><p class="bulletIndent1">Data on the efficacy of other glucocorticoids are limited to small trials, several of which were stopped early because of the findings of the trial above [<a href="#rid60">60-62</a>]. Individual trials of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> in critically ill patients failed to demonstrate a clear benefit [<a href="#rid60">60,61</a>]; in a meta-analysis that included three trials evaluating hydrocortisone, there was a nonstatistically significant trend toward reduced 28-day mortality compared with usual care or placebo (OR 0.69, 95% CI 0.43-1.12) [<a href="#rid48">48</a>]. Trials evaluating methylprednisone have not demonstrated a clear benefit. In a randomized trial from Brazil that included 393 patients with suspected or confirmed severe COVID-19 (77 percent of whom were on oxygen or ventilatory support), there was no difference in 28-day mortality rates with <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> compared with placebo (37 versus 38 percent) [<a href="#rid63">63</a>]. It is uncertain whether the apparent difference in results compared with the larger <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> trial is related to the glucocorticoid formulation and dose, other differences between the trial populations, or issues related to statistical power.</p><p></p><p class="headingAnchor" id="H3587406518"><span class="h3">Adjunctive immunomodulators</span></p><p class="headingAnchor" id="H2006857191"><span class="h4">Baricitinib and JAK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">Baricitinib</a> is a Janus kinase (JAK) inhibitor used for treatment of rheumatoid arthritis. In addition to immunomodulatory effects, it is thought to have potential antiviral effects through interference with viral entry. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>baricitinib</strong> – We suggest <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> as an option for patients requiring high-flow oxygen or noninvasive ventilation and for select patients who are on low-flow oxygen but are progressing toward needing higher levels of respiratory support despite initiation of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>). Baricitinib is also a reasonable alternative to <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, if it is not available, in patients who are on mechanical ventilation or ECMO. We generally reserve baricitinib for those who are within 96 hours of hospitalization or within 24 to 48 hours of initiation of ICU-level care, similar to the study population in the large trials. We do not use baricitinib in patients who have also received an interleukin (IL)-6 pathway inhibitor, as the safety and additive benefit of combining these agents are uncertain. As with tocilizumab, we only use baricitinib with caution in immunocompromised patients. This approach is largely consistent with recommendations from the NIH COVID-19 Treatment Guidelines Panel [<a href="#rid2">2</a>]. In the United States, baricitinib is US Food and Drug Administration (FDA) approved for hospitalized adults requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO [<a href="#rid64">64</a>]. <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a>, another JAK inhibitor, may be an alternative if other immunomodulators are not available. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> above.) </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">Baricitinib</a> is given at 4 mg orally once daily for up to 14 days. The dose is reduced in patients with renal insufficiency, and its use is not recommended if the estimated glomerular filtration rate (eGFR) is &lt;15 mL/min per 1.73 m<sup>2</sup>. Baricitinib is also not recommended in patients with COVID-19 with lymphopenia (absolute lymphocyte count &lt;200 cells/microL) or neutropenia (absolute neutrophil count &lt;500 cells/microL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Data suggest that <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> provides a mortality benefit for patients with severe disease, even if they are already on <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid65">65</a>]. In an open-label randomized trial of over 8000 hospitalized patients with COVID-19, baricitinib reduced 28-day mortality compared with usual care alone (12 versus 14 percent; relative risk 0.87, 95% CI 0.77-0.99) [<a href="#rid66">66</a>]. Almost all participants (95 percent) were receiving glucocorticoids, 20 percent were receiving <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>, and 23 percent had received <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>. These results were similar to those of prior trials of baricitinib [<a href="#rid67">67-71</a>], although the relative mortality reduction was slightly lower in this trial. The reasons for this difference are uncertain; however, this trial included a broader patient population, and it is feasible that certain patient populations are more likely than others to benefit from baricitinib.</p><p></p><p class="bulletIndent1">As an example, in a placebo-controlled trial of 1525 hospitalized adults with COVID-19 who were not receiving invasive mechanical ventilation but had at least one elevated inflammatory marker (median CRP was 65 mg/L), adding <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> to standard of care reduced 28-day mortality (8.1 versus 13.1 percent with placebo; hazard radio [HR] 0.57, 95% CI 0.41-0.78); the reduction in mortality was maintained at 60 days [<a href="#rid67">67</a>]. Most participants (79 percent) were also receiving glucocorticoids, mainly <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, and 20 percent received <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>. Among the subgroup of patients who were on high-flow oxygen or noninvasive ventilation at baseline, the mortality with baricitinib was 17.5 percent versus 29.4 percent with placebo (HR 0.52, 95% CI 0.33-0.80); mortality rates with baricitinib were also lower than with placebo for individuals who were not on oxygen or on low-flow oxygen at baseline, but these differences were not statistically significant. A smaller trial suggested that baricitinib also reduced mortality compared with placebo among 101 patients on mechanical ventilation or ECMO at enrollment (39 versus 58 percent, HR 0.54, 95% CI 0.31-0.96) [<a href="#rid72">72</a>]. </p><p></p><p class="bulletIndent1">These data are consistent with other findings of potential benefit with <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid68">68-71</a>]. In other randomized trials, adding baricitinib to <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> reduced time to recovery compared with placebo [<a href="#rid68">68</a>], and baricitinib plus remdesivir resulted in similar rates of mechanical ventilation-free survival with fewer associated adverse effects compared with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> plus remdesivir in patients on oxygen or noninvasive ventilation [<a href="#rid71">71</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> may also have clinical benefit, although data are more limited. In a randomized trial of 289 patients hospitalized with COVID-19, most of whom were receiving glucocorticoids, tofacitinib (10 mg twice daily for up to 14 days) reduced the combined outcome of death and respiratory failure at 28 days compared with placebo (18 versus 29 percent, relative risk 0.63, 95% CI 0.41-0.97) [<a href="#rid73">73</a>]. There was also a trend toward lower all-cause mortality (2.8 versus 5.5 percent, HR 0.49, 95% CI 0.15-1.63), but this was not statistically significant. In contrast, trials have not demonstrated a benefit with <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, another JAK inhibitor [<a href="#rid74">74,75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– In these studies, there was no apparent increase in the rate of adverse effects, including infection rates and venous thromboembolism, with <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>. In the large placebo-controlled trial discussed above, treatment-emergent infections (16 percent) and thromboembolic events (3 percent) occurred at similar frequencies in both the baricitinib and placebo groups [<a href="#rid67">67</a>]. However, the number of immunocompromised patients included in this trial was not specified.</p><p></p><p class="headingAnchor" id="H3289150964"><span class="h4">IL-6 pathway inhibitors (eg, tocilizumab)</span><span class="headingEndMark"> — </span>Markedly elevated inflammatory markers (eg, D-dimer, ferritin) and elevated pro-inflammatory cytokines (including interleukin [IL]-6) are associated with critical and fatal COVID-19, and blocking the inflammatory pathway may prevent disease progression [<a href="#rid76">76</a>]. Several agents that target the IL-6 pathway have been evaluated in randomized trials for treatment of COVID-19; data are most robust for the IL-6 receptor blocker <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>tocilizumab</strong> – We suggest <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (8 mg/kg as a single intravenous dose) as an option for individuals who require high-flow oxygen or more intensive respiratory support  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>). If supplies of medication allow, we also suggest tocilizumab on a case-by-case basis as an option for select patients on low-flow oxygen supplementation if they are clinically progressing toward high-flow oxygen despite initiation of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and have significantly elevated inflammatory markers (eg, C-reactive protein [CRP] level ≥75 mg/L). More specifically, we would give tocilizumab to such patients if they had progressively greater oxygen requirements for reasons related to COVID-19 but not if their oxygen requirement is stable or is worsening due to other causes of respiratory decompensation (eg, asthma exacerbation, congestive heart failure). We generally reserve tocilizumab for those who are within 96 hours of hospitalization or within 24 to 48 hours of initiation of ICU-level care, similar to the study population in the large trials. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> above.)</p><p></p><p class="bulletIndent1">We only use <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> in patients who are also taking <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (or another glucocorticoid) and generally limit it to a single dose. We do not use tocilizumab in patients who are receiving <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, as these agents have not been studied together and the safety of coadministration is uncertain. Tocilizumab should be avoided in individuals with hypersensitivity to tocilizumab, uncontrolled serious infections other than COVID-19, absolute neutrophil count (ANC) &lt;1000 cells/microL, platelet counts &lt;50,000, alanine aminotransferase (ALT) &gt;10 times the upper limit of normal (ULN), and elevated risk for gastrointestinal perforation. Tocilizumab should be used with caution in immunocompromised individuals as very few were included in randomized trials. Data regarding <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">sarilumab</a> are less robust than those for tocilizumab. </p><p></p><p>Recommendations from expert and governmental guideline groups vary slightly. In the United States, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> is FDA approved for hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO [<a href="#rid77">77</a>]. The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel recommends adding tocilizumab to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in recently hospitalized patients who are on high-flow oxygen or greater support and have either been admitted to the ICU within the prior 24 hours or have significantly increased inflammatory markers of inflammation; some panel members also suggested adding tocilizumab to patients on conventional oxygen supplementation if they had rapidly increasing oxygen needs and a CRP level ≥75 mg/L [<a href="#rid2">2</a>]. The Infectious Diseases Society of America (IDSA) suggests adding tocilizumab to standard of care (ie, glucocorticoids) for hospitalized adults who have progressive severe or critical COVID-19 and have elevated markers of systemic inflammation [<a href="#rid45">45</a>]. The National Health Service in the United Kingdom recommends consideration of tocilizumab as an adjunct to dexamethasone in patients with severe COVID-19 [<a href="#rid78">78</a>]. These include patients who have hypoxemia (oxygen saturation repeatedly &lt;92 percent on room air) or are on supplementary oxygen and have a CRP ≥75 mg/L as well as those who started on respiratory support (high-flow oxygen, noninvasive ventilation, or invasive mechanical ventilation) in the prior 24 hours. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Overall, evidence suggests a mortality benefit with IL-6 inhibitors, with most studies evaluating <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid50">50,79,80</a>]. In a meta-analysis of 27 randomized trials of over 10,000 patients hospitalized with COVID-19, 28-day all-cause mortality was lower among those who received tocilizumab compared with placebo or standard of care (odds ratio 0.83, 95% CI 0.74-0.92) [<a href="#rid80">80</a>]. The two largest trials in that analysis were conducted in patients with severe and critical COVID-19 and support the use of tocilizumab, as detailed below. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an open-label trial in the United Kingdom that included 4116 patients with suspected or confirmed COVID-19, hypoxemia (oxygen saturation &lt;92 percent on room air or oxygenation supplementation of any kind), and a CRP level ≥75 mg/L, adding one to two doses of weight-based <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> to usual care reduced the 28-day mortality rate compared with usual care alone (31 versus 35 percent, relative risk 0.85, 95% CI 0.76-0.94) [<a href="#rid81">81</a>]. Among those who were not on mechanical ventilation at baseline, tocilizumab similarly reduced the combined endpoint of progression to mechanical ventilation or death. There did not appear to be a statistically significant difference in mortality risk reduction by level of baseline respiratory support. Most of the trial participants (82 percent) were also using glucocorticoids, mainly <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, and subgroup analysis suggested that they were more likely to benefit from tocilizumab than were individuals who did not receive glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another open-label international randomized trial suggested a long-term mortality benefit of IL-6 pathway inhibitors among patients with severe COVID-19 who were admitted to the intensive care unit in the prior 24 hours and required initiation of either respiratory or cardiovascular support [<a href="#rid82">82</a>]. <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> (n = 353) and <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">sarilumab</a> (n = 48) each reduced in-hospital mortality compared with standard of care (28 and 22 versus 36 percent; adjusted odds ratio for hospital survival 1.64, 95% credible interval [CrI] 1.14-2.35 for tocilizumab and 2.01, 95% CrI 1.18-4.71 for sarilumab). In a follow-up analysis that included additional participants, IL-6 pathway inhibitors (n = 948 for tocilizumab and 485 for sarilumab) were associated with lower 180-day mortality (adjusted HR 0.76, 95% CrI 0.61-0.93) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Several other trials failed to identify a mortality benefit or other clear clinical benefit with these agents [<a href="#rid83">83-90</a>]. As an example, one double-blind, randomized trial of 243 patients with severe COVID-19 who were not intubated but had evidence of a pro-inflammatory state (with elevations in CRP, ferritin, D-dimer, or lactate dehydrogenase) did not detect a difference in the rate of intubation or death with a single dose of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> compared with placebo (10.6 versus 12.5 percent, HR 0.83, 95% CI 0.38-1.81) [<a href="#rid86">86</a>]. Although there were more subjects older than 65 years in the tocilizumab arm, the HR was not statistically significant after adjustment for age and other clinical features. Tocilizumab also did not reduce the risk of disease progression (eg, worsening oxygen requirements). </p><p></p><p class="bulletIndent1">The reasons for the different findings among trials are uncertain. The trials that suggested a benefit with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> reported somewhat higher overall mortality rates compared with other trials, potentially reflecting more severely ill populations. This possibility is supported by a post-hoc analysis of a trial that did not originally show a benefit, in which tocilizumab was associated with a reduction in death and mechanical ventilation only among those with a CRP level &gt;150 mg/L [<a href="#rid91">91</a>]. Trials that suggested a benefit also reported a high rate of concomitant glucocorticoid use, which most other trials did not; whether this is a relevant factor is uncertain. Finally, some of the trials that failed to show a benefit reported non-statistically significant trends towards a benefit, and these trials may have been underpowered to identify an effect. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Serious adverse events in trials were not greater with IL-6 pathway inhibitors than comparators. Although use of IL-6 pathway inhibitors may be associated with an increased risk of secondary infections [<a href="#rid92">92,93</a>], this risk was not observed in several randomized trials [<a href="#rid86">86-88</a>]. However, patients with active infections other than COVID-19 were typically excluded from trial participation. (See  <a class="medical medical_review" href="/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Tocilizumab'</a>.)</p><p></p><p class="headingAnchor" id="H1119722255"><span class="h4">Limited roles for alternative immunomodulators</span><span class="headingEndMark"> — </span>Other immunomodulatory agents have potential benefit for severely or critically ill patients with COVID-19, and in the United States, some have received EUA for this indication. However, we do not routinely use these other agents, in part because they do not offer clear advantages over other immunomodulatory agents that have demonstrated efficacy (eg, JAK inhibitors or IL-6 inhibitors). However, if <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> are not available, these are reasonable alternatives for patients who meet the authorization criteria. The NIH COVID-19 Treatment Guidelines Panel suggests <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> or <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> as alternatives to baricitinib or tocilizumab; it notes that there is insufficient evidence to recommend for or against <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> or <a class="drug drug_general" data-topicid="141200" href="/d/drug information/141200.html" rel="external">vilobelimab</a> [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a><strong> </strong>– This anti-TNF agent is not authorized for use in patients with COVID-19 but may have some efficacy. In a randomized trial evaluating several immunomodulators in patients with severe COVID-19, most of whom were on <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> and glucocorticoids, infliximab (5 mg/kg intravenously once) reduced 28-day mortality compared with placebo in the per-protocol analysis (10.1 percent among 517 patients versus 14.5 percent among 516 patients, OR 0.59, 95% CI 0.39-0.90) [<a href="#rid94">94</a>]. However, infliximab did not clearly reduce time to recovery (9 days for both groups, estimated recovery rate ratio [RRR] 1.12, 95% CI 0.99-1.28). The rates of severe adverse events, including secondary infections, were similar with infliximab and placebo. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> – This T-cell costimulation blocking agent is not authorized for use in patients with COVID-19 but may have some efficacy. In a randomized trial evaluating several immunomodulators in patients with severe COVID-19, most of whom were on <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> and glucocorticoids, abatacept (10 mg/kg intravenously once) reduced 28-day mortality compared with placebo in the per-protocol analysis (11 percent among 509 patients versus 15.1 percent among 510 patients, OR 0.62, 95% CI 0.41-0.94) [<a href="#rid94">94</a>]. However, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> did not clearly reduce time to recovery (9 days for both groups, estimated RRR 1.12, 95% CI 0.98-1.28). The rates of severe adverse events, including secondary infections, were similar with abatacept and placebo. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-1 inhibitors (eg, </strong><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a><strong>)</strong> – The interleukin-1 (IL-1) inhibitor anakinra is authorized for hospitalized patients with severe COVID-19 who are receiving supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR), a biomarker that has been associated with disease progression in some studies [<a href="#rid95">95</a>]. When used for this purpose, anakinra is dosed at 100 mg subcutaneously daily for 10 days. However, we do not routinely use anakinra because of other available options and because the suPAR biomarker is not widely available (including in the United States), and it is thus challenging to identify the patient population expected to benefit from anakinra. </p><p></p><p class="bulletIndent1">Support for <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> comes primarily from a randomized trial performed in Italy and Greece that evaluated subcutaneous anakinra for 10 days in hospitalized patients with COVID-19 who had an elevated suPAR level (≥6 ng/mL); most participants were also receiving <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid96">96</a>]. At 28 days, anakinra increased the likelihood of clinical recovery (50.4 versus 26.5 percent; unadjusted odds of a worse clinical severity score 0.36, 95% CI 0.26-0.49) and reduced mortality compared with placebo (3.2 versus 6.9 percent, hazard ratio 0.45, 95% CI 0.21-0.98). In the absence of suPAR testing, meeting three of the following eight criteria has been proposed as a surrogate for having an elevated suPAR level: age ≥75 years, severe pneumonia, current/previous smoking, Sequential Organ Failure Assessment (SOFA) score ≥3, neutrophil-to-lymphocyte ratio ≥7, hemoglobin ≤10.5 g/dL, history of ischemic stroke, blood urea ≥50 mg/dL and/or medical history of renal disease. However, outcomes with anakinra among patients meeting these criteria are unknown. </p><p></p><p class="bulletIndent1">However, some other trials of IL-1 inhibitors (including <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> in hospitalized patients with nonsevere and severe COVID-19 [<a href="#rid34">34,97,98</a>] and <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> in patients with severe COVID-19 [<a href="#rid98">98,99</a>]) have not identified a reduction in ventilator-free or overall survival or improved outcomes at 180 days. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141200" href="/d/drug information/141200.html" rel="external">Vilobelimab</a> – This monoclonal antibody complement inhibitor is authorized for hospitalized patients with COVID-19 who have initiated invasive mechanical ventilation or extracorporeal membrane oxygenation within the last 48 hours [<a href="#rid100">100</a>]. The dose is 800 mg intravenously, given up to six times on days 1, 2, 4, 8, 15, and 22, while the patient is still hospitalized. Hospitalization should not be extended simply to give all doses of vilobelimab. We do not routinely use vilobelimab given the availability of other immunomodulatory options and some uncertainties around the data.</p><p></p><p class="bulletIndent1">Authorization was based on results of a multinational randomized trial that included 368 adults hospitalized for COVID-19 who had started mechanical ventilation in the last 48 hours; almost all were also receiving <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid101">101</a>]. The 28-day mortality rate was lower with <a class="drug drug_general" data-topicid="141200" href="/d/drug information/141200.html" rel="external">vilobelimab</a> compared with placebo, although the difference was not statistically significant (32 versus 42 percent, hazard ratio 0.73, 95% CI 0.50-1.06). Other analyses (eg, without site stratification) did show a statistically significant difference. Nevertheless, the noted imprecision reduces confidence in the finding that vilobelimab reduces mortality. Furthermore, more individuals in the placebo group required additional organ support beyond mechanical ventilation, which introduces further uncertainty. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="141200" href="/d/drug information/141200.html" rel="external">Vilobelimab</a> was also associated with a slight excess of non-fatal secondary infections, including pneumonia and sepsis. </p><p></p><p></p><p class="headingAnchor" id="H2576622514"><span class="h3">Remdesivir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">Remdesivir</a> is a novel nucleotide analog that has in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<a href="#rid102">102</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>remdesivir</strong> – If available, we suggest <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> for hospitalized patients with severe COVID-19 who are not on mechanical ventilation because some data suggest it may reduce time to recovery and risk of mechanical ventilation  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>). Guidelines from the IDSA, the NIH, and the WHO recommend remdesivir for severe COVID-19 [<a href="#rid2">2,45,47,103</a>]. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> above.)</p><p></p><p class="bulletIndent1">In the United States, the FDA approved <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> for hospitalized children ≥12 years and adults with COVID-19, regardless of disease severity [<a href="#rid104">104</a>]. The suggested adult dose is 200 mg intravenously on day 1 followed by 100 mg daily for 5 days total (with extension to 10 days if there is no clinical improvement). If a patient is otherwise ready for discharge prior to completion of the course, remdesivir can be discontinued. Remdesivir can be used in patients with renal impairment, including those on dialysis, without dose adjustment [<a href="#rid105">105</a>]. Despite initial concerns about its cyclodextrin vehicle, which can accumulate in renal impairment, studies have reported safe use of remdesivir in patients with acute kidney injury and chronic kidney disease without worsening kidney function or other excess adverse effects [<a href="#rid106">106-108</a>]. Liver enzymes should be checked before and during remdesivir administration; alanine aminotransferase elevations &gt;10 times the upper limit of normal should prompt consideration of remdesivir discontinuation. Remdesivir can otherwise be used in patients with decompensated liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">Remdesivir</a> has been evaluated for both severe and non-severe COVID-19 in hospitalized patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe COVID-19</strong> – Data from randomized trials do not clearly or consistently demonstrate a major clinical benefit with <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> among hospitalized patients overall, although there may be a benefit (faster recovery, reduced risk of mechanical ventilation, and mortality reduction) for a select subgroup of patients with severe disease who are not on ventilatory support at the time of treatment initiation [<a href="#rid37">37,38,49,109-115</a>]. As an example, in the WHO-sponsored, multinational SOLIDARITY trial of patients hospitalized with COVID-19, there was a small difference in overall 28-day mortality between the 4146 patients randomly assigned to open-label remdesivir and the 4129 patients assigned to standard care, but it was not statistically significant (14.5 versus 15.6 percent; RR 0.91, 95% CI 0.82-1.02) [<a href="#rid38">38</a>]. However, among those who were not on ventilatory support, remdesivir reduced both mortality (RR 0.86, 95% CI 0.76-0.98) and progression to ventilation (RR 0.88, 95% CI 0.77-1.00). Similar findings were reported in a subsequent meta-analysis of randomized trials that included over 6000 patients with COVID-19 who required supplemental oxygen but not ventilatory support [<a href="#rid114">114</a>]. Among this population, remdesivir reduced 28-day mortality compared with standard care or placebo (adjusted OR 0.79, 95% CI 0.69-0.92). </p><p></p><p class="bulletIndent2">Although these trials evaluated 10 days of <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a>, 5 days of therapy may result in similar outcomes in patients who do not need mechanical ventilation or ECMO [<a href="#rid116">116</a>]. </p><p></p><p class="bulletIndent2">Observational data also suggest a potential benefit of <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> for certain subsets of this population. In particular, among patients with immunocompromising conditions hospitalized for COVID-19, including those on supplemental oxygen or ventilatory support, receipt of remdesivir within the first two days of admission was associated with lower 28-day mortality compared with no remdesivir in a large database study from the United States [<a href="#rid117">117</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsevere COVID-19</strong> – Among hospitalized patients with nonsevere disease (ie, no hypoxia or oxygen requirement), <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> may have a modest benefit, but the clinical significance of the benefit is uncertain [<a href="#rid37">37-39</a>]. In an open-label randomized trial, 584 patients with moderate severity COVID-19 (pulmonary infiltrates on imaging but oxygen saturation &gt;94 percent on room air) were assigned to receive remdesivir for up to 5 days, remdesivir for up to 10 days, or standard of care [<a href="#rid39">39</a>]. By day 11, the five-day remdesivir group had better clinical status according to a seven-point scale compared with standard of care (odds ratio 1.65, 95% CI 1.09 to 2.48). There was not a statistically significant difference at day 11 in clinical status between the 10-day remdesivir group and the standard of care group. Although discharge rates by day 14 were higher with remdesivir (76 percent in each of the remdesivir groups versus 67 percent with standard of care), these differences were not statistically significant. Interpretation of this trial is limited by the open-label design and an imbalance in co-therapies. Additionally, whether remdesivir reduces mortality in this population is uncertain, in part because the risk of COVID-19-associated mortality in individuals without severe disease is low. In a meta-analysis of randomized trials that included over 2000 hospitalized patients with COVID-19 who did not require oxygen or ventilatory support, there was a trend toward lower mortality in such patients receiving remdesivir compared with those on standard care, but the difference was not statistically significant (adjusted OR 0.86, 95% CI 0.53-1.4) [<a href="#rid114">114</a>]. Trials of remdesivir in outpatients with nonsevere COVID-19 are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Remdesivir'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Reported side effects include nausea, vomiting, and transaminase elevations. In one trial, the most common adverse events were anemia, acute kidney injury, fever, hyperglycemia, and transaminase elevations; the rates of these were overall similar between <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> and placebo [<a href="#rid37">37</a>]. However, in another trial, remdesivir was stopped early because of adverse events (including gastrointestinal symptoms, aminotransferase or bilirubin elevations, and worsened cardiopulmonary status) more frequent than with placebo (12 percent versus 5 percent) [<a href="#rid109">109</a>]. Cases of bradycardia attributable to remdesivir have also been reported [<a href="#rid118">118-120</a>]. </p><p></p><p class="headingAnchor" id="H3926972052"><span class="h3">Limited role for antibody-based therapies (monoclonal antibodies and convalescent plasma)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibodies </strong>– Results from available trials do not demonstrate a benefit of monoclonal antibodies in most hospitalized patients [<a href="#rid121">121,122</a>]. Although data had suggested a potential benefit for a subset of hospitalized patients (eg, those without detectable anti-SARS-CoV-2 antibodies at presentation) [<a href="#rid123">123,124</a>], the increasing prevalence of SARS-CoV-2 variants that escape clinically available monoclonal antibodies has rendered the therapy ineffective  (<a class="graphic graphic_table graphicRef131216" href="/d/graphic/131216.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Convalescent plasma</strong> – Convalescent plasma from individuals who have recovered from COVID-19 has been hypothesized to have clinical benefit for COVID-19, and in the United States, EUA has been granted for high-titer convalescent plasma among hospitalized patients with COVID-19 who have impaired humoral immunity [<a href="#rid125">125</a>]. However, the available evidence does not support a clear role for convalescent plasma in patients with severe disease, and because of the lack of consistent benefit, we suggest not using convalescent plasma outside the context of clinical trials for hospitalized immunocompetent patients. Limited randomized trial data and observational data suggest that convalescent plasma may have a role for individuals with immunocompromising conditions or deficits in antibody production (eg, those receiving anti-CD20 therapies, those with hematologic malignancies) [<a href="#rid126">126-130</a>]. Convalescent plasma is also being evaluated in outpatient populations with nonsevere COVID-19. (See <a class="local">'Patients with oxygen requirement/severe disease'</a> above and  <a class="medical medical_review" href="/d/html/128321.html" rel="external">"COVID-19: Convalescent plasma and hyperimmune globulin"</a> and  <a class="medical medical_review" href="/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer", section on 'Cancer therapy in infected patients'</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a>.)</p><p></p><p class="bulletIndent1">Despite some observational evidence suggesting that early administration of convalescent plasma with high antibody titers was associated with lower mortality rates, randomized trials in hospitalized patients with COVID-19 have not demonstrated a clear clinical benefit of convalescent plasma, including large trials that stopped enrollment for lack of mortality benefit [<a href="#rid131">131-141</a>]. In a meta-analysis of 21 randomized trials including over 19,000 hospitalized patients with moderate to severe COVID-19, convalescent plasma did not reduce all-cause mortality up to 28 days compared with either placebo or standard of care (RR 0.98, 95% CI 0.92-1.03) [<a href="#rid141">141</a>]. However, a subsequent open-label trial that was conducted between 2020 and 2022 and included 475 patients who had recently initiated mechanical ventilation did report a reduction in 28-day mortality with high-titer convalescent plasma collected early in the pandemic (80 percent with titer ≥1:320) compared with standard of care (35 versus 45 percent, p = 0.03); most of the mortality difference was among patients treated within 48 hours of mechanical ventilation [<a href="#rid142">142</a>]. Almost all participants also received <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, but use of other COVID-19-specific therapy was uncommon. In addition, few of the of participants had infection with Omicron variants, which have a spike protein substantially different from that of previous variants, so the trial could not address concern that neutralization would be lower if closely matched, contemporaneously collected convalescent plasma was not used. Thus, the value of convalescent plasma against Omicron variants and in the context of common use of other COVID-19 therapies, including immunomodulatory agents, remains uncertain. Furthermore, confidence in the mortality benefit reported in the trial is decreased since most other trials found minimal effects of convalescent plasma, including among ventilated patients. </p><p></p><p class="bulletIndent1">Trials of hyperimmune globulin have also not demonstrated benefit [<a href="#rid143">143,144</a>]. (See  <a class="medical medical_review" href="/d/html/128321.html" rel="external">"COVID-19: Convalescent plasma and hyperimmune globulin"</a>.)</p><p></p><p class="headingAnchor" id="H3001451751"><span class="h3">Others</span><span class="headingEndMark"> — </span>Many other agents with known or putative antiviral or immunomodulating effects have been proposed for use in patients with COVID-19 but have insufficient evidence of clinical benefit. Use of these agents for COVID-19 should be limited to clinical trials, if used at all; their efficacy has not been proven, and extensive off-label use may result in excess toxicity and critical shortages of drugs for proven indications. </p><p>A list of international clinical trials can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fclinical-trials-registry-platform&amp;token=4qjs%2BrZwTwTTP%2Brc1sEGa2VE98HKkryCI%2B%2FBy18BhnsEbhClzD7xRESlS5XyB%2B2F5EPEt%2B89fpE3%2FF0GlvU%2BMw%3D%3D&amp;TOPIC_ID=127429" target="_blank">WHO website</a> and at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3Dcovid-19%26term%3D%26cntry%3D%26state%3D%26city%3D%26dist&amp;token=vV%2Fnai5uSxgxuQaZ3ohI6agCcPk5%2BLK8UU%2BE9MUJMjtlWorWbSGQ78S%2BDgKPgmvHX7uiE5yR0lgL5hS0IeVKsPPLoCxGcVG5gsFfJT2Rkj4YGlhI1YyJ4EwfYDs8f6kt&amp;TOPIC_ID=127429" target="_blank">clinicaltrials.gov</a>. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ivermectin</strong> – In patients with COVID-19, we reserve <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> for prevention of <em>Strongyloides</em> reactivation in select individuals receiving glucocorticoids (see  <a class="medical medical_review" href="/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Preventive treatment'</a>). We do not use ivermectin for treatment of COVID-19, consistent with recommendations from the WHO [<a href="#rid145">145</a>]. Systematic reviews and meta-analyses comparing ivermectin with placebo or standard of care have highlighted that the data on ivermectin for COVID-19 are of low quality and overall do not indicate a clear benefit [<a href="#rid49">49,50,146,147</a>]. Although ivermectin administered in a hospital setting has not been associated with excess serious adverse events in studies, gastrointestinal and neurologic side effects have been reported in individuals who obtained ivermectin at high or uncertain doses without prescription (eg, from internet or veterinary sources) [<a href="#rid148">148</a>]. Ivermectin had originally been proposed as a potential therapy based on in vitro activity against SARS-CoV-2; however, the drug levels used in the in vitro studies far exceed those achieved in vivo with safe drug doses [<a href="#rid149">149</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other immunomodulatory agents</strong> – In addition to JAK inhibitors (see <a class="local">'Baricitinib and JAK inhibitors'</a> above), IL-6 pathway inhibitors (see <a class="local">'IL-6 pathway inhibitors (eg, tocilizumab)'</a> above), anti-TNF agents, IL-1 inhibitors, and complement inhibitors (see <a class="local">'Limited roles for alternative immunomodulators'</a> above), immunomodulatory agents from various other classes, including other cytokine inhibitors [<a href="#rid150">150</a>], other kinase inhibitors [<a href="#rid151">151-153</a>], bradykinin pathway inhibitors [<a href="#rid154">154</a>], and hematopoietic colony-stimulating factors agonist and antagonists [<a href="#rid155">155,156</a>], have been evaluated. Their use has been described mainly in case series and other observational studies. Although a randomized trial suggested a survival benefit of lenzilumab, an anti-granulocyte-macrophage colony stimulating factor (GM-CSF) monoclonal antibody, in patients with severe COVID-19, uncertainties in trial design and outcomes reduce confidence in these findings [<a href="#rid157">157</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> – In patients with COVID-19, vitamin D supplementation may be appropriate to meet the recommended intake or treat deficiency. However, we do not exceed the recommended upper level of intake, and there is no clear evidence that vitamin D supplementation or high-dose vitamin D improves COVID-19 outcomes. These data are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health", section on 'COVID-19'</a>.) </p><p></p><p>Novel agents under evaluation for severe COVID-19 in hospitalized patients include sabizabulin, a microtubule disruptor purported to have antiviral and anti-inflammatory effects through disruption of intracellular transport [<a href="#rid158">158</a>]. Sabizabulin reduced mortality in a randomized trial of hospitalized patients with severe COVID-19 that was stopped early for benefit, but the mortality rate in the placebo group was higher than expected; additional study is warranted to confirm the findings. </p><p>Agents that do not appear to have a clear clinical benefit in hospitalized patients with COVID-19 include <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid159">159-165</a>], <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid166">166-168</a>], <a class="drug drug_general" data-topicid="9982" href="/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> [<a href="#rid38">38,165,169,170</a>], interferon beta [<a href="#rid38">38,171,172</a>], <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid163">163,173-175</a>], the HCV antivirals <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> plus daclatasvir [<a href="#rid176">176-179</a>], the selective serotonin receptor blocker <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> [<a href="#rid180">180</a>], <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> [<a href="#rid181">181-183</a>], <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> [<a href="#rid184">184</a>], and zinc [<a href="#rid185">185</a>]. </p><p class="headingAnchor" id="H3633193855"><span class="h1">MANAGEMENT OF HYPOXEMIA, ARDS, AND OTHER COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients with severe disease typically need oxygen supplementation. Respiratory care for patients with severe disease is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)"</a>.)</p><p>Some patients may develop acute respiratory distress syndrome (ARDS) and warrant intubation with mechanical ventilation. Management of ARDS in patients with COVID-19 and other critical care issues are discussed in detail elsewhere  (<a class="graphic graphic_table graphicRef127595" href="/d/graphic/127595.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.) </p><p>In addition to ARDS, other complications of infection include arrhythmias, acute cardiac injury, acute kidney injury, thromboembolic events, and shock. Management of these complications is discussed elsewhere. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127551.html" rel="external">"COVID-19: Arrhythmias and conduction system disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Acute kidney injury'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p></p><p class="headingAnchor" id="H2678831777"><span class="h1">DISCHARGE</span><span class="headingEndMark"> — </span>The decision to discharge a patient with COVID-19 is generally the same as that for other conditions and depends on the need for hospital-level care and monitoring. </p><p>Continued need for infection control precautions should not prevent discharge home if the patient can appropriately self-isolate there; long-term care facilities may have specific requirements prior to accepting patients with COVID-19. Criteria for discontinuing precautions and infection control issues in long-term care facilities are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p>Older age (eg, &gt;65 years), underlying medical comorbidities, and discharge to a skilled nursing facility have been associated with an increased risk of readmission following hospitalization for COVID-19 [<a href="#rid186">186</a>]. Patients with COVID-19 generally warrant outpatient follow-up through telehealth or an in-person visit following discharge from the hospital. (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Post-discharge management'</a>.)</p><p class="headingAnchor" id="H3505908534"><span class="h1">SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H2322223737"><span class="h2">Pregnant and breastfeeding women</span><span class="headingEndMark"> — </span>The management of pregnant and breastfeeding women with COVID-19 is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues"</a>.)</p><p class="headingAnchor" id="H3126411167"><span class="h2">People with HIV</span><span class="headingEndMark"> — </span>The impact of HIV infection on the natural history of COVID-19 is uncertain. However, many of the comorbid conditions associated with severe COVID-19 (eg, cardiovascular disease) occur frequently among patients with HIV, and these, in addition to CD4 cell count, should be considered in risk stratification. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'People with HIV'</a>.)</p><p>Overall, the management of COVID-19 in patients with HIV is the same as in patients without HIV; HIV should not be a reason to exclude a patient from clinical trials or other interventions [<a href="#rid187">187</a>]. However, drug interactions with antiretroviral agents are important to assess before starting any new therapies. </p><p>Although certain antiretroviral agents have been hypothesized to have efficacy against SARS-CoV-2, antiretroviral regimens should not be adjusted based on concern for COVID-19. </p><p class="headingAnchor" id="H3198408182"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H2660796158"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/127758.html" rel="external">"Patient education: COVID-19 and pregnancy (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/127544.html" rel="external">"Patient education: COVID-19 and children (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1731570618"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for hospitalization </strong>– Many patients with known or suspected COVID-19 have mild disease that does not warrant hospital-level care; having such patients recover at home is preferred. Indications for hospitalization are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting", section on 'Indications for hospitalization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– The evaluation should assess for features associated with severe illness  (<a class="graphic graphic_table graphicRef127820" href="/d/graphic/127820.html" rel="external">table 1</a>) and identify organ dysfunction or other comorbidities that could complicate potential therapy. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboprophylaxis </strong>– Patients hospitalized with COVID-19 should receive pharmacologic prophylaxis for venous thromboembolism  (<a class="graphic graphic_algorithm graphicRef128045" href="/d/graphic/128045.html" rel="external">algorithm 1</a>). Dosing and selection of anticoagulants, including when to use therapeutic-dose anticoagulation, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipyretics </strong>– As in the general population, we suggest <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> for fever reduction in patients with COVID-19 rather than non-steroidal anti-inflammatory drugs (NSAIDs) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If NSAIDs are needed, we use the lowest effective dose. However, we do not discontinue NSAIDs in patients who are on them chronically for other conditions if there are no other reasons to stop them. Observational data do not indicate an association between NSAIDs and poor COVID-19 outcomes. (See <a class="local">'NSAID use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuing chronic medications </strong>– Specific concern for COVID-19 should not impact the decision to start or stop angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). People who are on an ACE inhibitor or ARB for another indication should not stop their medication. (See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Renin angiotensin system inhibitors'</a>.)</p><p></p><p class="bulletIndent1">We continue statins in hospitalized patients with COVID-19 who are already taking them. We also continue <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> unless there is concern for bleeding risk. (See <a class="local">'Statins and aspirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to patients with no oxygen requirement</strong> – For such patients who have clinical  (<a class="graphic graphic_table graphicRef127477" href="/d/graphic/127477.html" rel="external">table 2</a>) or laboratory  (<a class="graphic graphic_table graphicRef127820" href="/d/graphic/127820.html" rel="external">table 1</a>) risk factors for severe disease and were hospitalized for COVID-19, we suggest <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Individuals who have risk factors but were hospitalized for other reasons (ie, have incidental SARS-CoV-2 infection) may be eligible for therapies that have been authorized for high-risk outpatients. For patients without any risk factors, care is primarily supportive. All patients warrant close monitoring for disease progression. (See <a class="local">'Patients without oxygen requirement'</a> above and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to patients with oxygen requirement/severe disease </strong>– For patients who require oxygen supplementation because of COVID-19, the approach to COVID-19-specific therapy depends on the level of support; doses and duration are listed in the algorithm  (<a class="graphic graphic_algorithm graphicRef134578" href="/d/graphic/134578.html" rel="external">algorithm 3</a>) (see <a class="local">'Patients with oxygen requirement/severe disease'</a> above and <a class="local">'Specific treatments'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-flow oxygen</strong> – For patients receiving low-flow supplemental oxygen, we suggest low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). It is reasonable to defer dexamethasone for those who are stable on minimal oxygen supplementation (eg, 1 to 2 L/min), particularly if they are immunocompromised and within 10 days of symptom onset. </p><p></p><p class="bulletIndent2">For patients who have escalating oxygen requirements despite <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, have elevated inflammatory markers, and are within 96 hours of hospitalization, we suggest adding either <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If supplies of tocilizumab or baricitinib are limited, we prioritize them for more severely ill patients on higher levels of oxygen support. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-flow oxygen or NIV</strong> – For patients receiving high-flow supplemental oxygen or non-invasive ventilation (NIV), we recommend low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). If they are within 24 to 48 hours of admission to an intensive care unit (ICU) or receipt of ICU-level care (and within 96 hours of hospitalization), we suggest either <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> in addition to dexamethasone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We also suggest adding <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanical ventilation or ECMO</strong> – For patients who require mechanical ventilation or extracorporeal membrane oxygenation (ECMO), we recommend low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). For those who are within 24 to 48 hours of admission to an ICU (and within 96 hours of hospitalization), we suggest adding <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> or <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> to dexamethasone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We suggest not routinely initiating <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> in this population (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is not available, other glucocorticoids at equivalent doses are reasonable alternatives. If neither <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> is available, certain other immunomodulatory agents (eg, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> or <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) are potential alternatives. (See <a class="local">'Dexamethasone and other glucocorticoids'</a> above and <a class="local">'Adjunctive immunomodulators'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for other therapies</strong> – We generally do not use other agents off label for treatment of COVID-19. We also suggest not routinely using convalescent plasma for hospitalized patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Others'</a> above and <a class="local">'Limited role for antibody-based therapies (monoclonal antibodies and convalescent plasma)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hypoxemia </strong>– Patients with severe disease often need respiratory support. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)"</a> and  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control </strong>– Infection control is an essential component of management of patients with suspected or documented COVID-19. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p class="headingAnchor" id="H2494910249"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eric Meyerowitz, MD, Camille Kotton, MD, Michael Mansour, MD, Pritha Sen, MD, Ramy Elshaboury, PharmD, Ronak Gandhi, PharmD, and Boris Juelg, MD, for their contributions to this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).</li><li class="breakAll">National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on October 25, 2023).</li><li class="breakAll">ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection (Accessed on April 01, 2020).</li><li><a class="nounderline abstract_t">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.</a></li><li><a class="nounderline abstract_t">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.</a></li><li><a class="nounderline abstract_t">Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934.</a></li><li><a class="nounderline abstract_t">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.</a></li><li><a class="nounderline abstract_t">Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19. Circulation 2020; 141:1733.</a></li><li class="breakAll">American College of Cardiology. Troponin and BNP Use in COVID-19. Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 (Accessed on April 16, 2020).</li><li><a class="nounderline abstract_t">Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368:m1086.</a></li><li><a class="nounderline abstract_t">Rinott E, Kozer E, Shapira Y, et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020; 26:1259.e5.</a></li><li><a class="nounderline abstract_t">Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17:e1003308.</a></li><li><a class="nounderline abstract_t">Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis 2021; 80:943.</a></li><li><a class="nounderline abstract_t">Chandan JS, Zemedikun DT, Thayakaran R, et al. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis Rheumatol 2021; 73:731.</a></li><li><a class="nounderline abstract_t">Drake TM, Fairfield CJ, Pius R, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol 2021; 3:e498.</a></li><li class="breakAll">European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (Accessed on March 19, 2020).</li><li class="breakAll">WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 (Accessed on April 21, 2020).</li><li class="breakAll">Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (Accessed on March 18, 2020).</li><li class="breakAll">European Society of Hypertension. ESH Statement on COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (Accessed on March 18, 2020).</li><li class="breakAll">International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ (Accessed on March 18, 2020).</li><li class="breakAll">Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (Accessed on March 18, 2020).</li><li class="breakAll">Hypertension Canada. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf (Accessed on March 18, 2020).</li><li><a class="nounderline abstract_t">Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA 2023; 329:1183.</a></li><li><a class="nounderline abstract_t">Self WH, Shotwell MS, Gibbs KW, et al. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA 2023; 329:1170.</a></li><li><a class="nounderline abstract_t">INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ 2022; 376:e068407.</a></li><li><a class="nounderline abstract_t">REMAP-CAP Investigators, Hills TE, Lorenzi E, et al. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med 2023; 389:2341.</a></li><li><a class="nounderline abstract_t">Daniels LB, Sitapati AM, Zhang J, et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol 2020; 136:149.</a></li><li><a class="nounderline abstract_t">Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab 2020; 32:176.</a></li><li><a class="nounderline abstract_t">Rosenthal N, Cao Z, Gundrum J, et al. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open 2020; 3:e2029058.</a></li><li><a class="nounderline abstract_t">Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad Med J 2022; 98:354.</a></li><li><a class="nounderline abstract_t">Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. PLoS Med 2021; 18:e1003820.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399:143.</a></li><li><a class="nounderline abstract_t">REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2022; 327:1247.</a></li><li><a class="nounderline abstract_t">Writing Committee for the REMAP-CAP Investigators, Higgins AM, Berry LR, et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA 2023; 329:39.</a></li><li class="breakAll">US FDA. Remdesivir letter of EUA. https://www.fda.gov/media/137564/download (Accessed on January 24, 2022).</li><li><a class="nounderline abstract_t">Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239.</a></li><li><a class="nounderline abstract_t">Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020; 383:1813.</a></li><li><a class="nounderline abstract_t">WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384:497.</a></li><li><a class="nounderline abstract_t">Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:1048.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384:693.</a></li><li><a class="nounderline abstract_t">Kmietowicz Z. Covid-19: Selected NHS patients will be treated with remdesivir. BMJ 2020; 369:m2097.</a></li><li class="breakAll">Gilead. Veklury (remdesivir) product monograph. http://www.gilead.ca/application/files/2015/9594/6448/VEKLURY_English_PM_e240551-GS-000.pdf (Accessed on August 06, 2020).</li><li><a class="nounderline abstract_t">Lamb YN. Remdesivir: First Approval. Drugs 2020; 80:1355.</a></li><li class="breakAll">UK Government press release. World first coronavirus treatment approved for NHS use by government https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government (Accessed on June 16, 2020).</li><li class="breakAll">Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed on February 21, 2021).</li><li class="breakAll">World Health Organization. Corticosteroids for COVID-19: Living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (Accessed on September 08, 2020).</li><li><a class="nounderline abstract_t">Agarwal A, Hunt B, Stegemann M, et al. A living WHO guideline on drugs for covid-19. BMJ 2020; 370:m3379.</a></li><li><a class="nounderline abstract_t">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324:1330.</a></li><li><a class="nounderline abstract_t">Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370:m2980.</a></li><li class="breakAll">COVID-19 Living Network Meta-Analysis. http://www.covid19lnma.com/ (Accessed on September 07, 2021).</li><li><a class="nounderline abstract_t">Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8:CD014963.</a></li><li><a class="nounderline abstract_t">Covello RD, Pasin L, Fresilli S, et al. Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">Huang CW, Yu AS, Song H, et al. Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. JAMA Netw Open 2022; 5:e221455.</a></li><li><a class="nounderline abstract_t">COVID STEROID 2 Trial Group, Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA 2021; 326:1807.</a></li><li><a class="nounderline abstract_t">Taboada M, Rodríguez N, Varela PM, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Maskin LP, Bonelli I, Olarte GL, et al. High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial. J Intensive Care Med 2022; 37:491.</a></li><li><a class="nounderline abstract_t">Bouadma L, Mekontso-Dessap A, Burdet C, et al. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial. JAMA Intern Med 2022; 182:906.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Electronic address: <span class="__cf_email__" data-cfemail="1f6d7a7c70697a6d666b6d767e735f717b6f77317067317e7c316a74">[email protected]</span>, RECOVERY Collaborative Group. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2023; 401:1499.</a></li><li><a class="nounderline abstract_t">Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; 324:1317.</a></li><li><a class="nounderline abstract_t">Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:1298.</a></li><li><a class="nounderline abstract_t">Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324:1307.</a></li><li><a class="nounderline abstract_t">Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis 2021; 72:e373.</a></li><li class="breakAll">US Food and Drug Administration. https://www.fda.gov/media/143822/download (Accessed on May 18, 2022).</li><li><a class="nounderline abstract_t">Kramer A, Prinz C, Fichtner F, et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev 2022; 6:CD015209.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022; 400:359.</a></li><li><a class="nounderline abstract_t">Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021; 9:1407.</a></li><li><a class="nounderline abstract_t">Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021; 384:795.</a></li><li><a class="nounderline abstract_t">Stebbing J, Sánchez Nievas G, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv 2021; 7.</a></li><li><a class="nounderline abstract_t">Hasan MJ, Rabbani R, Anam AM, et al. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. BMC Infect Dis 2021; 21:427.</a></li><li><a class="nounderline abstract_t">Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med 2022; 10:888.</a></li><li><a class="nounderline abstract_t">Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med 2022; 10:327.</a></li><li><a class="nounderline abstract_t">Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021; 385:406.</a></li><li><a class="nounderline abstract_t">Han MK, Antila M, Ficker JH, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol 2022; 4:e351.</a></li><li><a class="nounderline abstract_t">Rein L, Calero K, Shah R, et al. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome. Crit Care Med 2022; 50:1701.</a></li><li><a class="nounderline abstract_t">Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033.</a></li><li class="breakAll">US Food and Drug Administration prescribing information for tocilizumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125472s049lbl.pdf (Accessed on January 01, 2023).</li><li class="breakAll">National Health Service. Interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 pneumonia (adults). February 17, 2021. https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103144 (Accessed on February 19, 2021).</li><li><a class="nounderline abstract_t">Ghosn L, Assi R, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev 2023; 6:CD013881.</a></li><li><a class="nounderline abstract_t">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021; 326:499.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637.</a></li><li><a class="nounderline abstract_t">REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021; 384:1491.</a></li><li class="breakAll">Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30-00 (Accessed on August 04, 2020).</li><li><a class="nounderline abstract_t">Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med 2021; 384:1503.</a></li><li class="breakAll">Reuters. Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study. https://www.reuters.com/article/us-health-coronavirus-roche-hldg/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-idUSKBN23O3GG (Accessed on August 04, 2020).</li><li><a class="nounderline abstract_t">Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020; 383:2333.</a></li><li><a class="nounderline abstract_t">Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021; 181:32.</a></li><li><a class="nounderline abstract_t">Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021; 181:24.</a></li><li><a class="nounderline abstract_t">Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021; 384:20.</a></li><li><a class="nounderline abstract_t">CORIMUNO-19 Collaborative group. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatol 2022; 4:e24.</a></li><li><a class="nounderline abstract_t">Mariette X, Hermine O, Tharaux PL, et al. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Intern Med 2021; 181:1241.</a></li><li><a class="nounderline abstract_t">Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2:e474.</a></li><li><a class="nounderline abstract_t">Busani S, Bedini A, Biagioni E, et al. Two Fatal Cases of Acute Liver Failure Due to HSV-1 Infection in COVID-19 Patients Following Immunomodulatory Therapies. Clin Infect Dis 2021; 73:e252.</a></li><li><a class="nounderline abstract_t">O'Halloran JA, Ko ER, Anstrom KJ, et al. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA 2023; 330:328.</a></li><li class="breakAll">FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR KINERET. https://www.fda.gov/media/163075/download (Accessed on December 15, 2022).</li><li><a class="nounderline abstract_t">Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 2021; 27:1752.</a></li><li><a class="nounderline abstract_t">CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021; 9:295.</a></li><li><a class="nounderline abstract_t">Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev 2022; 1:CD015308.</a></li><li><a class="nounderline abstract_t">Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA 2021; 326:230.</a></li><li class="breakAll">Emergency Use Authorization for Gohibic. https://www.fda.gov/media/166824/download (Accessed on April 26, 2023).</li><li><a class="nounderline abstract_t">Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2022; 10:1137.</a></li><li><a class="nounderline abstract_t">Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.</a></li><li><a class="nounderline abstract_t">Update to living systematic review on drug treatments for covid-19. BMJ 2022; 378:o1717.</a></li><li class="breakAll">Veklury. US FDA approved product information; Foster City, CA: Bristol Gilead Sciences, Inc; October 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf (Accessed on October 23, 2020).</li><li class="breakAll">Velkury (remdesivir). US Food and Drug Administration (FDA) approved product information. Revised July 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf (Accessed on July 14, 2023).</li><li><a class="nounderline abstract_t">Thakare S, Gandhi C, Modi T, et al. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep 2021; 6:206.</a></li><li><a class="nounderline abstract_t">Cheng M, Fowler R, Murthy S, et al. Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial. JAMA Netw Open 2022; 5:e2229236.</a></li><li><a class="nounderline abstract_t">Seethapathy R, Wang Q, Zhao S, et al. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. PLoS One 2023; 18:e0279765.</a></li><li><a class="nounderline abstract_t">Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569.</a></li><li><a class="nounderline abstract_t">Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ 2020; 370:m2924.</a></li><li><a class="nounderline abstract_t">Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8:CD014962.</a></li><li><a class="nounderline abstract_t">Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2022; 22:209.</a></li><li><a class="nounderline abstract_t">Kaka AS, MacDonald R, Linskens EJ, et al. Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med 2022; 175:701.</a></li><li><a class="nounderline abstract_t">Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med 2023; 11:453.</a></li><li><a class="nounderline abstract_t">Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022; 194:E242.</a></li><li><a class="nounderline abstract_t">Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383:1827.</a></li><li><a class="nounderline abstract_t">Mozaffari E, Chandak A, Gottlieb RL, et al. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. Clin Infect Dis 2023; 77:1626.</a></li><li><a class="nounderline abstract_t">Touafchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect 2021.</a></li><li><a class="nounderline abstract_t">Barkas F, Styla CP, Bechlioulis A, et al. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review. J Cardiovasc Dev Dis 2021; 8.</a></li><li><a class="nounderline abstract_t">Devgun JM, Zhang R, Brent J, et al. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. JAMA Netw Open 2023; 6:e2255815.</a></li><li><a class="nounderline abstract_t">ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med 2021; 384:905.</a></li><li><a class="nounderline abstract_t">ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis 2022; 22:622.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399:665.</a></li><li><a class="nounderline abstract_t">ACTIV-3/TICO Bamlanivimab Study Group, Lundgren JD, Grund B, et al. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med 2022; 175:234.</a></li><li class="breakAll">US Food and Drug Administration. Letter updating EUA for convalescent plasma. https://www.fda.gov/media/141477/download (Accessed on February 08, 2021).</li><li><a class="nounderline abstract_t">Clark E, Guilpain P, Filip IL, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol 2020; 190:e154.</a></li><li><a class="nounderline abstract_t">Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol 2021; 7:1167.</a></li><li><a class="nounderline abstract_t">Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6:e2250647.</a></li><li><a class="nounderline abstract_t">Denkinger CM, Janssen M, Schäkel U, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer 2023; 4:96.</a></li><li><a class="nounderline abstract_t">Lacombe K, Hueso T, Porcher R, et al. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial. BMJ Med 2023; 2:e000427.</a></li><li><a class="nounderline abstract_t">Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:460.</a></li><li><a class="nounderline abstract_t">Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371:m3939.</a></li><li><a class="nounderline abstract_t">Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2021; 384:619.</a></li><li><a class="nounderline abstract_t">Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med 2021; 18:e1003415.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397:2049.</a></li><li><a class="nounderline abstract_t">Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2021; 326:1690.</a></li><li><a class="nounderline abstract_t">Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA 2021; 325:1185.</a></li><li><a class="nounderline abstract_t">Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med 2021; 384:1015.</a></li><li><a class="nounderline abstract_t">Menichetti F, Popoli P, Puopolo M, et al. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2136246.</a></li><li><a class="nounderline abstract_t">Troxel AB, Petkova E, Goldfeld K, et al. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. JAMA Netw Open 2022; 5:e2147331.</a></li><li><a class="nounderline abstract_t">Iannizzi C, Chai KL, Piechotta V, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2023; 5:CD013600.</a></li><li><a class="nounderline abstract_t">Misset B, Piagnerelli M, Hoste E, et al. Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients. N Engl J Med 2023; 389:1590.</a></li><li><a class="nounderline abstract_t">ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet 2022; 399:530.</a></li><li><a class="nounderline abstract_t">Kimber C, Valk SJ, Chai KL, et al. Hyperimmune immunoglobulin for people with COVID-19. Cochrane Database Syst Rev 2023; 1:CD015167.</a></li><li class="breakAll">WHO. Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1 (Accessed on April 16, 2021).</li><li><a class="nounderline abstract_t">Popp M, Reis S, Schießer S, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2022; 6:CD015017.</a></li><li><a class="nounderline abstract_t">Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Infect Dis 2022; 74:1022.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. August 2021. Available at: https://emergency.cdc.gov/han/2021/han00449.asp (Accessed on October 26, 2023).</li><li><a class="nounderline abstract_t">Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo) 2020; 73:593.</a></li><li><a class="nounderline abstract_t">De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020; 2:e465.</a></li><li><a class="nounderline abstract_t">Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135:1912.</a></li><li><a class="nounderline abstract_t">Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020; 5.</a></li><li><a class="nounderline abstract_t">Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020; 146:137.</a></li><li><a class="nounderline abstract_t">van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, et al. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. JAMA Netw Open 2020; 3:e2017708.</a></li><li><a class="nounderline abstract_t">Cheng LL, Guan WJ, Duan CY, et al. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med 2021; 181:71.</a></li><li><a class="nounderline abstract_t">Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3:e410.</a></li><li><a class="nounderline abstract_t">Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med 2022; 10:237.</a></li><li><a class="nounderline abstract_t">Barnette KG, Gordon MS, Rodriguez D, et al. Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evid 2022.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020; 383:2030.</a></li><li class="breakAll">NIH halts clinical trial of hydroxychloroquine https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine (Accessed on July 08, 2020).</li><li class="breakAll">WHO. “Solidarity” clinical trial for COVID-19 treatments: Update on hydroxychloroquine. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (Accessed on June 18, 2020).</li><li><a class="nounderline abstract_t">Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369:m1849.</a></li><li><a class="nounderline abstract_t">Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020; 383:2041.</a></li><li><a class="nounderline abstract_t">Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:2165.</a></li><li><a class="nounderline abstract_t">Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med 2021; 47:867.</a></li><li><a class="nounderline abstract_t">Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open 2020; 3:e2013136.</a></li><li><a class="nounderline abstract_t">Mikolajewska A, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 10:CD015045.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med 2021; 9:1419.</a></li><li><a class="nounderline abstract_t">Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; 396:1345.</a></li><li><a class="nounderline abstract_t">Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1365.</a></li><li><a class="nounderline abstract_t">Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56:105949.</a></li><li><a class="nounderline abstract_t">Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 2020; 396:959.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:605.</a></li><li><a class="nounderline abstract_t">Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020; 75:3379.</a></li><li><a class="nounderline abstract_t">Eslami G, Mousaviasl S, Radmanesh E, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother 2020; 75:3366.</a></li><li><a class="nounderline abstract_t">Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother 2020; 75:3373.</a></li><li><a class="nounderline abstract_t">Mobarak S, Salasi M, Hormati A, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2022; 77:758.</a></li><li><a class="nounderline abstract_t">Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:2292.</a></li><li><a class="nounderline abstract_t">Freedberg DE, Conigliaro J, Wang TC, et al. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology 2020; 159:1129.</a></li><li><a class="nounderline abstract_t">Mather JF, Seip RL, McKay RG. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. Am J Gastroenterol 2020; 115:1617.</a></li><li><a class="nounderline abstract_t">Yeramaneni S, Doshi P, Sands K, et al. Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System. Gastroenterology 2021; 160:919.</a></li><li><a class="nounderline abstract_t">LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Adhikari NKJ, Hashmi M, et al. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA 2023; 330:1745.</a></li><li><a class="nounderline abstract_t">Carlucci PM, Ahuja T, Petrilli C, et al. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. J Med Microbiol 2020; 69:1228.</a></li><li><a class="nounderline abstract_t">Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission - United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1695.</a></li><li class="breakAll">IDSA and HIVMA. COVID-19: Special Considerations for People Living with HIV. April 4, 2020. https://www.idsociety.org/globalassets/covid-19-special-considerations (Accessed on April 06, 2020).</li></ol></div><div id="topicVersionRevision">Topic 127429 Version 129.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://covid19treatmentguidelines.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on October 25, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection (Accessed on April 01, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031570" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109013" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical Characteristics of Coronavirus Disease 2019 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32167524" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171076" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251612" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251612" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184201" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32535147" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ibuprofen use and clinical outcomes in COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32898149" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33478953" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185016" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039790" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039791" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34996756" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37888913" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Simvastatin in Critically Ill Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32946859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592657" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301018" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33541927" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34648516" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34800427" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35315874" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36525245" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36525245" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32091533" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445440" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Remdesivir for the Treatment of Covid-19 - Final Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264556" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32821939" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32678530" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dexamethasone in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32457029" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Covid-19: Selected NHS patients will be treated with remdesivir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32457029" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Covid-19: Selected NHS patients will be treated with remdesivir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870481" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Remdesivir: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870481" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Remdesivir: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870481" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Remdesivir: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870481" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Remdesivir: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887691" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A living WHO guideline on drugs for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876694" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732190" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Drug treatments for covid-19: living systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732190" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Drug treatments for covid-19: living systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396514" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systemic corticosteroids for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258575" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34673895" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34916266" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34898320" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35788622" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37060915" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35361632" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876697" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876689" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876695" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785710" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785710" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35695334" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Janus kinase inhibitors for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35908569" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34480861" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33306283" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33187978" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33962573" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35617986" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123660" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34133856" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35368384" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36226977" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192578" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : COVID-19: consider cytokine storm syndromes and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192578" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : COVID-19: consider cytokine storm syndromes and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192578" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : COVID-19: consider cytokine storm syndromes and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37260086" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Interleukin-6 blocking agents for treating COVID-19: a living systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228774" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933206" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631065" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631065" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631066" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631066" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085857" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080017" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080005" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332779" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34812424" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34028504" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835257" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Tocilizumab in patients with severe COVID-19: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840571" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Two Fatal Cases of Acute Liver Failure Due to HSV-1 Infection in COVID-19 Patients Following Immunomodulatory Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37428480" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37428480" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34480127" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493450" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35080773" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Interleukin-1 blocking agents for treating COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34283183" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34283183" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36087611" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020029" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35830977" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Update to living systematic review on drug treatments for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35830977" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Update to living systematic review on drug treatments for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35830977" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Update to living systematic review on drug treatments for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073066" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36036936" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36848366" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32423584" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732352" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Remdesivir for severe covid-19: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34350582" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Remdesivir for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34534511" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226522" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36828006" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35045989" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459919" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37556727" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33647441" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33673216" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36787141" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33356051" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34953520" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35151397" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34928698" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34928698" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32593180" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34137799" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633846" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36581734" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37920150" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492084" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093056" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33232588" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657114" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000257" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34606578" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33635310" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33523609" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34842924" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35076699" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37162745" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Convalescent plasma for people with COVID-19: a living systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37889107" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093205" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36700518" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Hyperimmune immunoglobulin for people with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36700518" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Hyperimmune immunoglobulin for people with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35726131" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Ivermectin for preventing and treating COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181716" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181716" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32533071" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835256" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302379" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32503877" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32470486" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32789513" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32910179" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33754144" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34863332" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031652" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031652" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031652" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32409561" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706953" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33165621" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34251506" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32579195" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34658014" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Colchicine for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34672950" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32187464" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031764" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32661006" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : A Randomized Clinical Trial of the Efficacy and Safety of Interferonβ-1a in Treatment of Severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34672949" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205204" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32896292" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33545096" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812039" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812051" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812025" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34849957" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33180097" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446698" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852338" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058865" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37877585" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32930657" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33180754" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission - United States, March-August 2020.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
